2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

humanized IgG4-κ antibody

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

41

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99106
    Acrixolimab

    		PD-1/PD-L1 Cancer
    Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .
    Acrixolimab
  • HY-P990071
    Fepixnebart

    		EGFR Cancer
    Fepixnebart is a humanized IgG4κ antibody targeting TGF-alpha (TGFA).
    Fepixnebart
  • HY-P99884
    Sasanlimab

    PF-06801591

    		 PD-1/PD-L1 Others Cancer
    Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
    Sasanlimab
  • HY-P991038
    Zadoprubart

    		CD28 Inflammation/Immunology
    HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Zadoprubart
  • HY-P991705
    Nebaprubart

    		Fc Receptor (FcR) Inflammation/Immunology
    Nebaprubart is a humanized IgG4κ antibody targeting FCAR/CD89. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
    Nebaprubart
  • HY-P991710
    Ponumkibart

    		Interleukin Related Inflammation/Immunology
    Ponumkibart is a humanized IgG4κ antibody targeting IL-17RB. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
    Ponumkibart
  • HY-P991698
    Liscastobart

    		PD-1/PD-L1 Cancer
    Liscastobart is a humanized IgG4κ antibody targeting PDCD1/PD-1/CD279. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
    Liscastobart
  • HY-P991721
    Ticalicibart

    		PCSK9 Cardiovascular Disease
    Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
    Ticalicibart
  • HY-P990960
    Lucorafusp alfa

    		Transmembrane Glycoprotein Inflammation/Immunology
    HY-P990960 is an TIGIT-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Lucorafusp alfa
  • HY-P990949
    Umikibart

    YYB-101; ABX101

    		 c-Met/HGFR Inflammation/Immunology
    HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Umikibart
  • HY-P991688
    Gimvekibart

    		Interleukin Related Inflammation/Immunology
    Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
    Gimvekibart
  • HY-P99264
    Inotuzumab

    humanized Anti-CD22 Recombinant antibody

    		 ADC Antibody CD22 Apoptosis Cancer
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
    Inotuzumab
  • HY-P991675
    Camtarkibart

    		Interleukin Related Inflammation/Immunology
    Camtarkibart is an anti-IL4R IgG4κ type humanized antibody with immunomodulator activity. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Camtarkibart
  • HY-P990910
    Comekibart

    		Interleukin Related Inflammation/Immunology
    HY-P990910 is an IL4R-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Comekibart
  • HY-P990983
    Drotokibart

    		Interleukin Related Inflammation/Immunology
    HY-P990983 is an IL4RA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Drotokibart
  • HY-P99264A
    Inotuzumab (powder)

    humanized Anti-CD22 Recombinant antibody (powder)

    		 ADC Antibody CD22 Apoptosis Cancer
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma . x
    Inotuzumab (powder)
  • HY-P991024
    Solabafusp alfa

    		TNF Receptor Inflammation/Immunology
    HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Solabafusp alfa
  • HY-P991727
    Zamristobart

    		Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Inflammation/Immunology Cancer
    Zamristobart is an anti-LILRB1 (leukocyte immunoglobulin-like receptor B1) IgG4κ type humanized antibody with immunostimulant and antineoplastic activities. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Zamristobart
  • HY-P991708
    Olsutamig

    		PSMA CD3 Cancer
    Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
    Olsutamig
  • HY-P991620
    JS006

    		Transmembrane Glycoprotein Cancer
    JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
    JS006
  • HY-P990072
    Lipustobart

    LZM-009

    		 PD-1/PD-L1 Cancer
    Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
    Lipustobart
  • HY-P990070
    Zigakibart

    BION-1301

    		 TNF Receptor Inflammation/Immunology Cancer
    Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .
    Zigakibart
  • HY-P99573
    Tebotelimab

    MGD-013

    		 LAG-3 Inflammation/Immunology Cancer
    Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
    Tebotelimab
  • HY-P990374
    Anti-CLEC7A Antibody

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-CLEC7A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-CLEC7A Antibody
  • HY-P990452
    Anti-IL-5 Antibody

    		Interleukin Related Inflammation/Immunology
    Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-IL-5 Antibody
  • HY-P991201
    REGN-7257

    		Interleukin Related Inflammation/Immunology
    REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
    REGN-7257
  • HY-P990631
    Mibavademab

    		Neuropeptide Y Receptor Inflammation/Immunology
    Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Mibavademab
  • HY-P990426
    Anti-GREM1/Gremlin Antibody

    		TGF-beta/Smad Inflammation/Immunology
    The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-GREM1/Gremlin Antibody
  • HY-P990669
    Torudokimab

    		Interleukin Related Inflammation/Immunology
    Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Torudokimab
  • HY-P990564
    Senlizumab

    BAY-103356; CDP-571

    		 TNF Receptor Inflammation/Immunology
    Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Senlizumab
  • HY-P990555
    BI-765063

    OSE-172

    		 CD47 Inflammation/Immunology
    BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    BI-765063
  • HY-P990543
    Anti-VEGFR2/KDR/CD309 Antibody (AT001)

    		VEGFR Inflammation/Immunology
    The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-VEGFR2/KDR/CD309 Antibody (AT001)
  • HY-P990486
    Anti-PDCD1/PD-1/CD279 Antibody

    		PD-1/PD-L1 Inflammation/Immunology
    Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-PDCD1/PD-1/CD279 Antibody

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: